| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.072 | 0.02 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.072 | 0.02 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | Panobinostat | FIMM | pan-cancer | AAC | 0.25 | 0.03 |